Other chronic pain sickle cell disease
Conditions
Interventions
This is a randomized, controlled, double-blind clinical trial. The group with sickle cell disease and chronic pain (40 individuals) will be divided into two subgroups (n = 20 participants in each grou
and the cathode will be placed over the right supraorbital region. The current intensity will be maintained at 2 mA, and the stimulation period will be 20 minutes. For sham transcranial direct current
Sponsors
Fundação Universidade Federal do ABC
Universidade Federal da Bahia
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The study will include individuals with sickle cell disease (SCD), both genders, diagnosed by hemoglobin electrophoresis; aged 18 to 60 years; and with chronic primary musculoskeletal pain, diagnosed according to ICD 11 criteria, lasting three months or more. The group of individuals with SCD will consist of 40 individuals. The control group will include healthy individuals (without chronic pain and without SCD), matched by sex and age to the SCD and chronic pain group. The control group will consist of 20 individuals. Individuals with cochlear implants; cardiac pacemakers; or metal implants in the brain/ a history of traumatic brain injury; pregnancy; or a history of seizures or epilepsy will not be included in the study. The use of medications that modify the neuronal activation threshold (e.g., antidepressants, anticonvulsants, and antipsychotics) will be controlled
Exclusion criteria
Exclusion criteria: Individuals who wish to discontinue participation at any time or who experience any complications with the procedures will be excluded from the study. In this case, the data will be processed according to the intention to treat model, with the most recent results being repeated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To verify whether non-invasive neuromodulation modifies the effectiveness of the small-world network of individuals with sickle cell disease and chronic pain, through clustering and minimum path length parameters from electroencephalography data | — |
Secondary
| Measure | Time frame |
|---|---|
| To verify whether changes in brain connectivity promoted by non-invasive neuromodulation correlate with improvements in pain intensity;To compare the clustering coefficient, shortest path length, and small-world index of individuals with sickle cell disease and chronic pain with those of healthy individuals. | — |
Countries
BR
Contacts
Public ContactJamille Santana
Universidade Federal do ABC
Outcome results
None listed